Sökresultat

Filtyp

Din sökning på "*" gav 547951 sökträffar

Reflexive Views of Virtual Communities of Practice among Informal and Formal Caregivers of People with a Dementia Disease

Knowledge seems to mitigate the consequences of dementia and new educational strategies are required. This study aimed to qualitatively explore the reflexive views and experiences of virtual Communities of Practice (vCoP) among informal and formal caregivers of people with dementia and explore vCoP as a tool for learning and knowledge development. Data were collected in a sequence of virtual works

Phenotypic plasticity in tropical butterflies is linked to climatic seasonality on a macroevolutionary scale

Phenotypic plasticity can be adaptive in fluctuating environments by providing rapid environment-phenotype matching and this applies particularly in seasonal environments. African Bicyclus butterflies have repeatedly colonized seasonal savannahs from ancestral forests around the late Miocene, and many species now exhibit seasonal polyphenism. On a macroevolutionary scale, it can be expected that s

Synthesis and spectroscopic properties of carotenoid bis-phenylhydrazone astaxanthin : extending conjugation to a C=N group

We report on the synthesis and detailed spectroscopic characterization of bis-phenylhydrazone astaxanthin (BPH-Asx), a derivative of astaxanthin (Asx), in which the conjugated carbonyl group of Asx is replaced by a conjugated C N bond. BPH-Asx was successfully synthesized and characterized using various spectroscopic techniques, revealing subtle changes in absorption spectra and significant altera

The Giant Awakens : Law and Economics of Excessive Pricing During the COVID-19 Crisis

Price gouging of essential items, and the global debate on pricing of vaccines and treatments during the COVID-19 crisis, provide an optimal proxy to revisit the law and economics discourse on excessive pricing as an abuse of dominant position. Beyond a normative soul-searching of the efficiency v fairness debate, this chapter analyses excessive pricing cases during the COVID-19 pandemic in the EU

Excessive Pharmaceutical Pricing as an Abuse of Dominant Position-The Case of CD Pharma (Denmark)

On 31 January 2018, the Danish Competition and Consumer Authority adopted a decision1 finding the Swedish company generic distributor CD Pharma in breach of Art. 102(a) Treaty on the Functioning of the European Union (TFEU) by abusing its dominant position and having imposed excessive and unfair prices for the drug Syntocinon. The company increased the price of the drug by 2000% in the period Apri

Did the Danish Supreme Court Give the Fashion Industry the Kantian Boot?

The long-running case,1 which revolved around the brightly colored, fashionable leather boots by iconic Danish designer Ilse Jacobsen, ended with the Danish and European fashion industry on the receiving end of the legal boot. The Danish Supreme Court stopped short of awarding copyright to Ilse Jacobsen as a reward for her ‘free and independent creative effort’ in regard to the design of the now i

No-one is safe until everyone is safe – patent waiver, compulsory licensing and COVID-19

Recentmonths have seen intensified global calls for an intellectual propertywaiver of COVID-19 related vaccines, treatments and related products.Where one side of the debate elevates Intellectual Property Rights as on obstacle to affordable and expeditious global access to vaccines and treatments, the other side of the debate points to the existing TRIPS flexibilities such as compulsory licensing,

Let´s dance! excessive royalties and the economic value of music

Case C-372/19 Belgische Vereniging van Auteurs, Componisten en Uitgevers CVBA (SABAM) v Weareone.World BVBA and Wecandance NV, Judgment of the Court of Justice of the European Union (Fifth Chamber) of 25 November 2020 The most recent excessive pricing case considered by Court of Justice of European Union (CJEU) revolved around fees imposed by a national royalty collective society (SABAM) on two Be

Excessive Pharmaceutical Prices as an Anticompetitive Practice in TRIPS and European Competition Law

The issue of securing access to patented pharmaceutical products has been in the forefront of global legal debate for many years. This debate intensified further following the enactment of the TRIPSTRIPS agreement and the global enforcement of Intellectual Property Rights such as patents through the World Trade Organization. To combat the problem, compulsory licensingCompulsory licensing has been

The future of fossil fuels, chemicals, and feedstocks : Outlining a research agenda on the role of China in the global petrochemical industry

Petrochemical production is tightly entangled with fossil fuel extraction and constitutes the primary driver of oil demand growth. Therefore, scholars have increasingly started exploring the linkages between fossil fuels and chemicals, tracing their importance for the political economy of energy transitions. A defining feature in the global petrochemical industry is that the majority of the recent

Key issues for stakeholder engagement in the development of health and healthcare guidelines

Established in 2015, the Multi-Stakeholder Engagement (MuSE) Consortium is an international network of over 120 individuals interested in stakeholder engagement in research and guidelines. The MuSE group is developing guidance for stakeholder engagement in the development of health and healthcare guideline development. The development of this guidance has included multiple meetings with stakeholde

Are excessive pricing cases few and far between? A quantitative analysis of fifty years of European jurisprudence 1971–2021

The prohibition against excessive pricing dates back to the years of Babylonian King Hammurabi. Nevertheless, the prohibition is described by many as being “controversial” and against “mainstream economics”, which is why it should be applied rather sparsely. It has also rather routinely been claimed that the actual number of excessive pricing cases is “scarce”, “limited” and so on. Despite the his

Excessive pricing during the COVID-19 crisis in the EU - An empirical inquiry

The COVID-19 crisis noted many reports of dramatic price increases of essential items such as face masks, hand sanitisers and disinfectants. Already in March 2020 the Competition Authorities in Europe, by way of a joint statement by European Competition Network and individual public announcements, cautioned against price gouging practices and re-affirmed their commitment to pursue such practices v

Towards Fair Pricing of Medicines? Lessons from the European Commission's Aspen Decision

Excessive pharmaceutical pricing cases in EU have progressed from a theoretical possibility to becoming a recurrent enforcement reality, following heightened law and policy attention on affordability of medicines. This matter gained considerable momentum in the wake of COVID-19 crisis as result of the increased health spending, with debates on affordability raging at WTO and WIPO levels. Unfair pr

The Limits of Control – Competition law versus Sector Regulation in the wake of the European Commission Excessive Pricing Decision in Aspen

Despite being heavily regulated, the pharmaceutical sector in Europe has in recent years noted many enforcement decisions against excessive pharmaceutical pricing as an anti-competitive practice under Article 102(a) TFEU. Although described as a ‘rarity’ in competition law in most parts of the doctrine, numerous excessive pricing cases have emerged in Italy, UK, Denmark, and the Netherlands in rec

Beyond Justice versus Efficiency – Reconciling Law and Economics approaches to Fairness

Recent years have seen the dominance of neoclassical, marginalist and welfarist schools of Competition Law and Economics being challenged more vigorously than ever [See two major collecting works on fairness in economics in: Fennell and McAdams (2013) and Cappelen and Tungodden (2019)]. Although the core assumptions of the neoclassical school regarding overt reliance on rationality and efficiency

Temporary dominance and excessive pharmaceutical pricing - CD Pharma (Denmark)

On 31 January 2018, the Danish Competition and Consumer Authority adopted a decision that found the Swedish company CD Pharma, a generic distributor, to be in breach of Article 102(a) TFEU due to having abused its dominant position and imposed excessive and unfair prices for the drug Syntocinon. The company had increased the price of the drug by 2000% on the Danish market in the period April 2014-On 31 January 2018, the Danish Competition and Consumer Authority adopted a decision that found the Swedish company CD Pharma, a generic distributor, to be in breach of Article 102(a) TFEU due to having abused its dominant position and imposed excessive and unfair prices for the drug Syntocinon. The company had increased the price of the drug by 2000% on the Danish market in the period April 2014-